NASDAQ:NUVL • US6707031075
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NUVALENT INC-A (NUVL).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-08 | Wedbush | Reiterate | Outperform -> Outperform |
| 2026-03-30 | Wells Fargo | Initiate | Overweight |
| 2026-02-27 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-12-19 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-24 | Truist Securities | Initiate | Buy |
| 2025-11-18 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-18 | Baird | Maintains | Outperform -> Outperform |
| 2025-11-18 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-11-17 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-11-17 | Stifel | Maintains | Buy -> Buy |
| 2025-11-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-12 | Canaccord Genuity | Initiate | Buy |
| 2025-10-31 | UBS | Maintains | Buy -> Buy |
| 2025-10-31 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-27 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-16 | Stifel | Reiterate | Buy |
| 2025-10-15 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-09-08 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-09-03 | Raymond James | Initiate | Outperform |
| 2025-08-19 | Piper Sandler | Initiate | Overweight |
| 2025-06-25 | Baird | Maintains | Outperform -> Outperform |
| 2025-06-24 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-06-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-14 | UBS | Upgrade | Neutral -> Buy |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 1,239.49% | N/A 185.65% | N/A 77.57% | N/A 38.93% | N/A 31.65% | N/A 24.84% | N/A 26.61% | ||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A -81.40% | N/A -84.62% | N/A -79.98% | N/A -64.78% | N/A -4.57% | N/A 24.81% | N/A 88.18% | N/A 291.17% | N/A 560.97% | N/A 100.15% | N/A 24.61% | N/A 21.47% | |
| EBIT YoY % growth | -10.36M | -16.91M -63.22% | -45.82M -170.96% | -86.11M -87.93% | -149.492M -73.61% | -280.368M -87.55% | -414.307M -47.77% | N/A -13.04% | N/A 22.75% | N/A 76.86% | N/A 160.96% | N/A 864.88% | N/A 103.09% | N/A 42.03% | N/A 28.17% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -1.64 11.01% | -2.16 -31.71% | -3.90 -80.56% | -5.85 -50.00% | N/A 4.55% | N/A 13.91% | N/A 69.43% | N/A 384.19% | N/A 25.90% | N/A 102.75% | N/A 33.32% | N/A 23.71% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.34 -13.90% | -1.41 -1.51% | -1.43 15.83% | -1.39 12.33% | -0.06 95.83% | -1.33 5.66% | -1.16 19.09% | -0.89 35.94% |
| Revenue Q2Q % growth | 3.369M | 11.102M | 113.54M | 18.205M | 27.073M 703.59% | 40.582M 265.54% | ||
| EBITDA Q2Q % growth | -108.153M -29.52% | -111.68M -12.68% | -111.925M -4.97% | -107.843M 6.29% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -111.368M -17.46% | -116.109M -11.03% | -118.343M -5.01% | -115.392M -12.88% | 88.842M 179.77% | -118.626M -2.17% | -121.278M -2.48% | -121.89M -5.63% |
All data in USD
24 analysts have analysed NUVL and the average price target is 143.16 USD. This implies a price increase of 33.04% is expected in the next year compared to the current price of 107.61.
NUVALENT INC-A (NUVL) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of NUVALENT INC-A (NUVL) is -1.34 USD and the consensus revenue estimate is 0 USD.
The consensus rating for NUVALENT INC-A (NUVL) is 85.8333 / 100 . This indicates that analysts generally have a positive outlook on the stock.